Neximmune Stock Total Debt
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Total Debt Analysis
Neximmune's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Neximmune Total Debt | 68.81 K |
Most of Neximmune's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Neximmune has a Total Debt of 68.81 K. This is 100.0% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Neximmune Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in total debt category among its peers.
Neximmune Fundamentals
Return On Equity | -1.96 | ||||
Return On Asset | -0.7 | ||||
Current Valuation | (491.95 K) | ||||
Shares Outstanding | 1.37 M | ||||
Shares Owned By Insiders | 17.00 % | ||||
Shares Owned By Institutions | 11.17 % | ||||
Number Of Shares Shorted | 15.99 K | ||||
Price To Book | 1.38 X | ||||
EBITDA | (28.17 M) | ||||
Net Income | (32.34 M) | ||||
Cash And Equivalents | 53.13 M | ||||
Cash Per Share | 2.20 X | ||||
Total Debt | 68.81 K | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 6.54 X | ||||
Book Value Per Share | 2.00 X | ||||
Cash Flow From Operations | (31.43 M) | ||||
Short Ratio | 2.26 X | ||||
Earnings Per Share | (24.11) X | ||||
Target Price | 2.0 | ||||
Beta | 1.94 | ||||
Market Capitalization | 3.25 M | ||||
Total Asset | 8.59 M | ||||
Retained Earnings | (222.59 M) | ||||
Working Capital | 316.73 K | ||||
Net Asset | 8.59 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
CEOs Directory Screen CEOs from public companies around the world | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |